MTCI investigator successful in EU funded research project
MTCI investigator successful in EU funded research project to investigate toxicity mechanisms of approved anti-angiogenesis cancer drugs
The 'Angiotox' project is coordinated by Dr. Annette Byrne, Royal College of Surgeons in Ireland (RCSI) and Director of Translational Research at OncoMark.
The ‘Angiotox’ project will investigate the toxicity and mechanism of action of anti-angiogenic drugs used in the treatment of cancer patients. The project, worth €1.75 million euro, is funded under the FP7 Marie Curie Industry Academia Pathways and Partnerships scheme, and will bring together 7 partners from around Europe including partners at F. Hoffman La Roche and Zeptosense- a division of Bayer.
"In this wide-ranging project, we have assembled complementary research groups across Europe from both academic and industry sectors, which will work closely together via intersectoral exchanges to mediate key new insights into anti-angiogenic drugs. These funds will go toward ensuring we understand the mechanism of these drugs with a view towards translating this information for patient benefit." commented Dr. Byrne.
The goal of this consortium is to facilitate comprehensive histopathologic and mechanistic assessment of angiogenesis inhibitor related toxicities following treatment with the two main class of angiogenesis inhibitor; monoclonal antibodies and tyrosine kinase inhibitors.
